# Sean Barbour

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sean-barbour/

## Facts

| Field | Value |
| --- | --- |
| Citations | 3,819 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 19 |
| i10-index | 27 |
| Last Known Institution | University of British Columbia |
| OpenAlex ID | https://openalex.org/A5112763431 |
| Works | 90 |

## Researcher papers

- [Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group](https://scholariq.org/papers/oxford-classification-of-iga-nephropathy-2016-an-update-from-the-iga-nephropathy/)
- [Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy](https://scholariq.org/papers/effect-of-oral-methylprednisolone-on-clinical-outcomes-in-patients-with-iga/)
- [Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy](https://scholariq.org/papers/effect-of-oral-methylprednisolone-on-decline-in-kidney-function-or-kidney/)
- [Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference](https://scholariq.org/papers/management-and-treatment-of-glomerular-diseases-part-1-conclusions-from-a-kidney/)
- [Venous Thromboembolism in Patients with Membranous Nephropathy](https://scholariq.org/papers/venous-thromboembolism-in-patients-with-membranous-nephropathy/)
- [Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy](https://scholariq.org/papers/results-from-part-a-of-the-multi-center-double-blind-randomized-placebo/)
- [Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease](https://scholariq.org/papers/trans-ethnic-mendelian-randomization-study-reveals-causal-relationships-between/)
- [A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy](https://scholariq.org/papers/a-phase-2b-randomized-double-blind-placebo-controlled-clinical-trial-of/)
- [An update on predicting renal progression in IgA nephropathy](https://scholariq.org/papers/an-update-on-predicting-renal-progression-in-iga-nephropathy/)
- [Group VI Phospholipases A2: Homeostatic Phospholipases with Significant Potential as Targets for Novel Therapeutics](https://scholariq.org/papers/group-vi-phospholipases-a2-homeostatic-phospholipases-with-significant-potential/)
- [The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice](https://scholariq.org/papers/the-population-level-costs-of-immunosuppression-medications-for-the-treatment-of/)
- [Canadian Society of Nephrology Commentary on the Evolving Kidney Disease Improving Global Outcomes Adult Glomerulonephritis Guidelines](https://scholariq.org/papers/canadian-society-of-nephrology-commentary-on-the-evolving-kidney-disease/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Vasculitis and related conditions](https://scholariq.org/topics/vasculitis-and-related-conditions/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Renal Transplantation Outcomes and Treatments](https://scholariq.org/topics/renal-transplantation-outcomes-and-treatments/)

## Researcher university

- [University of British Columbia](https://scholariq.org/institutions/university-of-british-columbia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.